VSTM Quote, Financials, Valuation and Earnings

Applied Therapeutics has a net margin of -82.56% compared to Verastem's net margin of -56222.13%. Verastem's return on equity of -120.71% beat Applied Therapeutics's return on equity of -797.82%.

Verastem has a consensus price target of $12.57, signalling upside risk potential of 80.62%. On the other hand Applied Therapeutics has an analysts' consensus of $5.50 which suggests that it could grow by 906.59%. Given that Applied Therapeutics has higher upside potential than Verastem, analysts believe Applied Therapeutics is more attractive than Verastem.

Verastem has a beta of 0.605, which suggesting that the stock is 39.46% less volatile than S&P 500. In comparison Applied Therapeutics has a beta of 1.881, suggesting its more volatile than the S&P 500 by 88.052%.

Verastem has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Applied Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verastem pays -- of its earnings as a dividend. Applied Therapeutics pays out -- of its earnings as a dividend.

Verastem quarterly revenues are $10M, which are larger than Applied Therapeutics quarterly revenues of $122K. Verastem's net income of -$24M is higher than Applied Therapeutics's net income of -$68.6M. Notably, Verastem's price-to-earnings ratio is -- while Applied Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verastem is -- versus -- for Applied Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

CytomX Therapeutics has a net margin of -82.56% compared to Verastem's net margin of 49.55%. Verastem's return on equity of -120.71% beat CytomX Therapeutics's return on equity of --.

Verastem has a consensus price target of $12.57, signalling upside risk potential of 80.62%. On the other hand CytomX Therapeutics has an analysts' consensus of $4.94 which suggests that it could grow by 680.14%. Given that CytomX Therapeutics has higher upside potential than Verastem, analysts believe CytomX Therapeutics is more attractive than Verastem.

Verastem has a beta of 0.605, which suggesting that the stock is 39.46% less volatile than S&P 500. In comparison CytomX Therapeutics has a beta of 1.045, suggesting its more volatile than the S&P 500 by 4.544%.

Verastem has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CytomX Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verastem pays -- of its earnings as a dividend. CytomX Therapeutics pays out -- of its earnings as a dividend.

Verastem quarterly revenues are $10M, which are smaller than CytomX Therapeutics quarterly revenues of $38.1M. Verastem's net income of -$24M is lower than CytomX Therapeutics's net income of $18.9M. Notably, Verastem's price-to-earnings ratio is -- while CytomX Therapeutics's PE ratio is 1.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verastem is -- versus 0.39x for CytomX Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Reviva Pharmaceuticals Holdings has a net margin of -82.56% compared to Verastem's net margin of --. Verastem's return on equity of -120.71% beat Reviva Pharmaceuticals Holdings's return on equity of --.

Verastem has a consensus price target of $12.57, signalling upside risk potential of 80.62%. On the other hand Reviva Pharmaceuticals Holdings has an analysts' consensus of $12.14 which suggests that it could grow by 993.95%. Given that Reviva Pharmaceuticals Holdings has higher upside potential than Verastem, analysts believe Reviva Pharmaceuticals Holdings is more attractive than Verastem.

Verastem has a beta of 0.605, which suggesting that the stock is 39.46% less volatile than S&P 500. In comparison Reviva Pharmaceuticals Holdings has a beta of -0.095, suggesting its less volatile than the S&P 500 by 109.539%.

Verastem has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Reviva Pharmaceuticals Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verastem pays -- of its earnings as a dividend. Reviva Pharmaceuticals Holdings pays out -- of its earnings as a dividend.

Verastem quarterly revenues are $10M, which are larger than Reviva Pharmaceuticals Holdings quarterly revenues of --. Verastem's net income of -$24M is lower than Reviva Pharmaceuticals Holdings's net income of -$8.4M. Notably, Verastem's price-to-earnings ratio is -- while Reviva Pharmaceuticals Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verastem is -- versus -- for Reviva Pharmaceuticals Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Spero Therapeutics has a net margin of -82.56% compared to Verastem's net margin of -219.3%. Verastem's return on equity of -120.71% beat Spero Therapeutics's return on equity of 4.36%.

Verastem has a consensus price target of $12.57, signalling upside risk potential of 80.62%. On the other hand Spero Therapeutics has an analysts' consensus of $5.00 which suggests that it could grow by 539.06%. Given that Spero Therapeutics has higher upside potential than Verastem, analysts believe Spero Therapeutics is more attractive than Verastem.

Verastem has a beta of 0.605, which suggesting that the stock is 39.46% less volatile than S&P 500. In comparison Spero Therapeutics has a beta of 0.685, suggesting its less volatile than the S&P 500 by 31.497%.

Verastem has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spero Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verastem pays -- of its earnings as a dividend. Spero Therapeutics pays out -- of its earnings as a dividend.

Verastem quarterly revenues are $10M, which are larger than Spero Therapeutics quarterly revenues of $7.8M. Verastem's net income of -$24M is lower than Spero Therapeutics's net income of -$17.1M. Notably, Verastem's price-to-earnings ratio is -- while Spero Therapeutics's PE ratio is 9.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verastem is -- versus 0.47x for Spero Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.